Research programme: cytokine receptor modulators - Zymeworks
Latest Information Update: 22 Dec 2021
At a glance
- Originator Zymeworks
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Cytokine receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 14 Dec 2021 Cytokine receptor modulators - Zymeworks is available for licensing as of 14 Dec 2021. https://www.zymeworks.com/contact
- 14 Dec 2021 Preclinical trials in Autoimmune disorders in Canada (Parenteral) as of December 2021 (Zymeworks pipeline, December 2021)
- 14 Dec 2021 Preclinical trials in Inflammation in Canada (Parenteral) as of December 2021 (Zymeworks pipeline, December 2021)